SCHEMBL3901611

SCHEMBL3901611

CC(C)(C)OC(=O)N1CCC(Oc2cc(OCC(F)(F)F)ccc2C(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.49
GPR119 Q8TDV5 5/20 0.47
PDE4D Q08499 3/20 0.47
PDE4B Q07343 3/20 0.47
PDE4A P27815 2/20 0.47
PDE4C Q08493 2/20 0.47
NEK2 P51955 2/20 0.46
EPHX2 P34913 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911173 0.90 LIPE (0.48) LIPEGPR119PDE4DPDE4BPDE4A
SCHEMBL3902310 0.88 PDE4D (0.49) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL3159730 0.87 PDE4B (0.50) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL3903784 0.86 PDE4B (0.49) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL3165435 0.86 PDE4B (0.54) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL3166578 0.85 YAP1 (0.54) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL7343893 0.85 GPR119 (0.52) LIPEGPR119PDE4DPDE4BPDE4A
SCHEMBL8081429 0.84 GPR119 (0.51) LIPEGPR119PDE4DPDE4BPDE4A
SCHEMBL75960 0.84 GPR119 (0.62) LIPEGPR119EPHX2CHEK2
SCHEMBL3156353 0.84 GPR119 (0.49) GPR119PDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511066-B2 Antithrombotic aromatic ethers ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-20070027185-A1 Antithrombotic aromatic ethers ELILILLY AND COMPANY (US) 2007-02-01 US disclosed
EP-1670783-A2 ANTITHROMBOTIC AROMATIC ETHERS ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005049604-A2 ANTITHROMBOTIC AROMATIC ETHERS ELI LILLY AND COMPANY (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027185-A1 Antithrombotic aromatic ethers F2, F11, TFPI LIPE 1098/4885GPR119 1378/4885PDE4D 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.